RTP Mobile Logo

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of mantle cell lymphoma (MCL).

While MCL represents only approximately 6% of all non-Hodgkin lymphoma cases, it remains one of the 4 most frequently diagnosed subtypes and is widely viewed as harboring the worst disease characteristics and exhibiting the most destructive growth pattern. The vast majority of patients will need active treatment at some point, and it has long been established that fit individuals should receive high-dose chemoimmunotherapy followed by autologous stem cell transplant, with chemoimmunotherapy alone being employed for the elderly or those unable to tolerate more intensive approaches. Despite broad agreement among MCL investigators regarding this risk- and age-stratified algorithm, lingering debate still exists about the contribution of and indications for maintenance therapy in these individuals. Similarly, the treatment of first and subsequent relapses is significantly less well defined, and it is in this setting that treatment options have recently expanded, with many newer agents demonstrating significant activity against MCL. While the availability of multiple therapeutic options is welcomed by patients and clinicians alike, it may also challenge clinical decision-making. As such, a great need exists for resources that deliver expert perspectives and dedicated discussion of the relative benefits and risks of each available treatment as well as those with promising early-phase clinical trial data.

These proceedings from a CME/CNE symposium held during the 2018 Pan Pacific Lymphoma Conference use an innovative strategy to formally document and present the perspectives, experiences and preferred treatment approaches of 25 lymphoma-specific investigators. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of MCL with the formulation of up-to-date clinical management strategies.


  • Individualize the selection of systemic therapy for patients with newly diagnosed MCL, considering the patient’s clinical presentation, fitness and willingness to undergo autologous stem cell transplant and psychosocial status (eg, desire for active treatment).
  • Formulate an evidence-based approach to the use of maintenance therapy for transplant-eligible and transplant-ineligible patients with MCL.
  • Recall the mechanisms of action, efficacy and safety of approved agents commonly employed for the treatment of relapsed/refractory (R/R) MCL to determine the current and/or potential utility of each in clinical practice.
  • Appreciate the recent FDA approval of the second-generation BTK inhibitor acalabrutinib for patients with R/R MCL, and discern how this agent can be appropriately and safely integrated into routine clinical practice.
  • Design a plan of care to recognize and manage side effects and toxicities associated with the use of existing and recently approved systemic therapies in the management of MCL to support quality of life and continuation of therapy.
  • Recall available and emerging data with other investigational agents currently under evaluation for MCL, and where applicable, refer eligible patients for trial participation.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education (UNMC CCE), University of Nebraska Medical Center College of Nursing Continuing Nursing Education (UNMC CON CNE) and Research To Practice.

PHYSICIANS: The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME credit is no longer available for this issue

NURSES: The University of Nebraska Medical Center College of Nursing Continuing Nursing Education is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CNE credit is no longer available for this issue

CME: This CME activity consists of a video component.
CME credit is no longer available for this issue

CNE: This CNE activity consists of a video component.
CNE credit is no longer available for this issue

It is the policy of the UNMC CCE and UNMC CON CNE to ensure balance, independence, objectivity and scientific rigor in all their educational symposia. All faculty, planners and managers participating in these activities are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME/CNE about the products or services of the commercial interest. UNMC CCE, UNMC CON CNE and Research To Practice ensured that any conflicts of interest were resolved before the educational activity occurred.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Jeremy Abramson, MD
Director of the Lymphoma Program
Jon and Jo Ann Hagler Chair in Lymphoma
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Gilead Sciences Inc, Humanigen Inc, Juno Therapeutics, Karyopharm Therapeutics, Merck, Novartis, Seattle Genetics, Verastem Inc.

Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
St Louis, Missouri

Consulting Agreements: Celgene Corporation, Genentech, Pharmacyclics LLC, an AbbVie Company.

John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, New York

Consulting Agreements: ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biotest Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Gilead Sciences Inc, Juno Therapeutics, Karyopharm Therapeutics, MEI Pharma, Novartis, Pfizer Inc, Sutro Biopharma Inc, United Therapeutics Corporation.

Julie M Vose, MD, MBA
Neumann M and Mildred E Harris Professor
Chief, Division of Hematology/Oncology
Nebraska Medical Center
Omaha, Nebraska

Consulting Agreements: AbbVie Inc, Epizyme Inc, Karyopharm Therapeutics, Legend Pharmaceuticals, Nordic Nanovector, Novartis, Roche Laboratories Inc, Sandoz, Vaniam Group; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Incyte Corporation, Kite Pharma Inc, Merck, Novartis, Seattle Genetics.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE CME/CNE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and the UNMC CCE do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: August 2018
Expiration date: August 2019